Kornimate/medical-research-clean huggingface dataset:
pharmacogenetic supported prescribing in kids

Conditions: Mental Health Impairment

Summary: implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.

children with moderate to severe mental health conditions (e.g. depression, anxiety, ocd) or neurodevelopmental disorders (e.g., autism spectrum disorders, adhd) are frequently prescribed medications as either the sole form of treatment or in combination with psychotherapy. however, up to 50% of these children will not respond or experience burdensome adverse drug reactions to these medications. current use of mental health-related medications (e.g., antidepressants, antipsychotics) in children can be best described as a trial-and-error process that can impact the well-being of those taking the medications and their families at a considerable economic cost. however, this trial-and-error process could, in part, be avoided through the application of pharmacogenetic testing, a specific type of genetic testing that has the potential to improve drug efficacy and reduce the morbidity, mortality and cost associated with adverse drug reactions. the aim of this project is to implement and evaluate an evidence-based pharmacogenetic testing service to improve drug treatment outcomes in children receiving mental health care. our objectives are to: 1. implement canada's first pharmacogenetics testing service to improve drug treatment outcomes in children receiving mental health care. 2. collect performance, outcome, and economic indicators related to the pharmacogenetics testing service. 3. establish a research platform for the discovery of new genetic and non-genetic markers of drug treatment outcomes relevant to mental health care in children.

Eligibility criteria:
inclusion criteria: * medical records available * the initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated * treating psychiatrist, family physician, or pediatrician licensed in alberta, british columbia, saskatchewan, or manitoba requests pharmacogenetic testing exclusion criteria: * medically unstable or lacking capacity to provided informed consent * unwillingness of child to provide saliva sample for genetic analysis * history of liver or bone marrow (hematopoietic cell) transplant

Keywords: child adolescent mental health psychiatry pharmacogenetics depression anxiety ocd psychosis bipolar disorder
providing optimal peep during mechanical ventilation for obese patients using esophageal balloon

Conditions: Obesity, Morbid; Ventilator-Induced Lung Injury; Respiratory Failure

Summary: this is a research study to determine if identifying an optimal level of positive end-expiratory pressure (peep) targeted specifically to individualized patient characteristics will shorten the time on the ventilator. participants will have catheter placed through the nose into the esophagus to measure the pressure inside the chest. this catheter will remain until the patient is freed from the ventilator. participants will be randomized to usual care or to have the level of peep determined by the esophageal balloon pressure readings. the total time spent on the ventilator will be recorded.

study design: randomized-controlled clinical trial. patients will be enrolled within 4 days of mechanical ventilation and randomized 1:1 to titration of peep based on esophageal balloon pressures or based on the "high peep" ardsnet peep/fraction of inspired oxygen (fio2) table. all patients will have esophageal balloons placed with baseline measurement of ptp. patients randomized to the intervention arm will then undergo titration of peep based on ptp measurements to achieve "optimal peep," defined as end expiratory ptp of 0 to +2 cm water (h2o).

Eligibility criteria:
inclusion criteria: * body mass index greater than or equal to 40 * acute respiratory failure requiring mechanical ventilation exclusion criteria: * refusal to give consent by the subject or their legally authorized representative * abdominal compartment syndrome * chest tube for pneumothorax * having been on a ventilator for \>4 days * suspicion of or known intracranial hypertension * anticipated extubation within 24 hours * chronic ventilator dependence * condition that precludes placement of an esophageal balloon (esophageal or nasopharyngeal pathology preventing insertion of the esophageal balloon catheter, severe thrombocytopenia or coagulopathy) * incarceration

Keywords: transpulmonary pressure esophageal balloon esophageal pressure monitoring mechanical ventilation
post-hysterectomy nursing support program

Conditions: Hysterectomy

Summary: objective: this study was conducted to evaluate the effectiveness of the nursing support program developed for women undergoing hysterectomy. background: hysterectomy is an important surgical intervention that affects women physically, sexually and psychosocially. method: the study is a single blind, randomized controlled study conducted at the department of obstetrics and gynecology in a university hospital between november 2017 and november 2018. 60 women who had hysterectomy were divided into experimental and control groups and it was evaluated on the 1-2 day, 6-7 day and 2nd month. in the study, the nursing support program was applied only to women in the experimental group.

aim: this study was conducted to evaluate the effectiveness of the nursing support program developed for women who had hysterectomy. methods: a prospective, randomised controlled study was conducted in the gynaecology clinic of a university hospital between november 2017 and november 2018. it was conducted in a single-blind, randomised controlled trial with a total of 60 women in the experimental and control groups. a nursing support program had been developed for women who have had a hysterectomy. the program developed for the experimental group and the routine program for routine maintenance and control group were applied. the initial evaluation was carried out postoperative on the 1st-2nd day, the second assessment was carried out on the 6th-7th day and the third evaluation was carried out at 2 months. the first interview was carried out in the hospital, and the second and third interviews were carried out with home visits. the sociodemographic data form, postoperative evaluation form, female sexual function index (fsfi), epidemiological studies and central depression scale (eamds), menopausal symptoms evaluation scale (msds) and sf-12 quality of life scale were used to collect data.

Eligibility criteria:
inclusion criteria: * clinical diagnosis benign hysterectomy and bilateral oophorectomy * having no communication problems. exclusion criteria: * clinical diagnosis vaginal hysterectomy * clinical diagnosis psychiatric disorders and therefore used drugs

Keywords: hysterectomy nursing support program, menopausal symptoms sexuality depression quality of life
a study of lanadelumab in teenagers and adults with hereditary angioedema (hae) in argentina

Conditions: Angioedemas, Hereditary

Summary: the main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (hae) in argentina as part of routine routine practice. this study is about collecting data only. the study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. the study will collect data from the participant's medical records. participants do not need to visit their doctor in addition to their normal visits.


Eligibility criteria:
inclusion criteria: * participants (\>=12 years) with investigator confirmed diagnosis of hae. * have received at least one dose of lanadelumab according to approved indications. * signed the mandatory consent that has been agreed with national regulatory authorities (anmat) as applicable. exclusion criteria: - hypersensitivity to the active substance or to any of the excipients.

Keywords: lanadelumab post-authorization study
phase i compare os in post-cyberknife radiosurgery tx in 1-3 vs 4 or more brain metastases

Conditions: Brain and Nervous System

Summary: the investigators will learn from this study if the cyberknife radiosurgery (ck rs) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. the importance of this new knowledge will be to determine the treatment efficacy of ck rs with 1-3 versus 4 or more brain metastases. the outcome of this trial would give data to support either the continuation or modification of the ck rs treatment of patients with brain metastases.

this is registry-based cohort study of patients with brain metastases treated at stanford university medical center (sumc) with cyberknife radiosurgery (ck rs). it has two components: (1) a retrospective follow-up of patients treated since 2006, and (2) the accrual of a new cohort of patients treated over a 5-year period from january 15, 2013 to december 31, 2017 and followed for at least one year thereafter. the primary aim of this study is to estimate the effect of the number of brain tumor metastases on survival after adjusting for known risk factors for mortality.

Eligibility criteria:
inclusion criteria: 1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by the neurological examination and visibility of the metastatic lesion(s) on mri and ct scans 2. a karnofsky performance status (kps) score of greater than or equal to 60. exclusion criteria: the exclusion criteria are the converse of the above, i.e. patients without a brain tumor metastasis or brain tumor metastases or a kps of less than 60.
feasibility of obtaining and characterizing circulating tumorigenic cells in patients with pancreatic adenocarcinoma

Conditions: Pancreatic Adenocarcinoma

Summary: the purpose of this study is to collect blood samples and study cancer cells found in these blood samples from patients with pancreatic cancer. prior research has discovered that tumor cells can be collected from the blood of patients with pancreatic and other cancers. the physicians have developed techniques for isolating and analyzing cancer cells using a simple blood test. they will study how these cells relate to how chemotherapy works. they hope to use this information to guide choices of treatment for patients in the future.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at mskcc. * patient eligible for chemotherapy treatment. * prior surgery, chemotherapy and/or radiation therapy for pancreatic adenocarcinoma is permitted. * ecog performance status 0-2. * a minimum age of 18 years old. exclusion criteria: * known to be hiv positive on antiretroviral therapy * prior organ allograft * any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Keywords: blood draw pancreas tumorigenic cells 11-141
observational prospective study.at the end of the study the patients will be classified according to ph,serum bicarbonate and serum sodium into 6 groups and statistical analysis will be performed using spss

Conditions: Liver Cirrhosis

Summary: 1-to identify the prognostic value of serum bicarbonate and serum electrolytes at time of admission and their association with development of complications ,length of hospital stay ,prognosis and mortality in hospitalized cirrhotic patient

the purpose of this study will be explore the impact of data obtained for the arterial blood gas parameters and serum bicarbonate and electrolytes at the time of hospital admission on adverse clinical outcomes ,duration of length of hospital stay and mortality in patients with cirrhosis .furthermore incorporation these parameters into model of end stage liver disease could help to improve the prognostic value of meldscore in comparison to the prognostic value of traditional equation of original meld and child score

Eligibility criteria:
inclusion criteria: patients with confirmed diagnosis of cirrhosis (age \>18 years ) who will be admitted to internal medicine department or will be admitted to intermediate care unit * willing and agree to be included in the study exclusion criteria: * patients without evidence of cirrhosis * cirrhotic patients whom -younger than 18 years old * have diabetic ketoacidosis * with acute coronary syndrome * with fulminant liver failure * with heart failure * with organ transplantation * when arterial blood gases not be available * patient refusal * patient with hcc
combination of brivanib with 5-fluorouracil/leucovorin (5fu/lv) and 5-fluorouracil/leucovorin/irinotecan (folfiri)

Conditions: Gastro-Intestinal Cancer

Summary: the purpose of this study is to determine a safe and maximum tolerable dose of brivanib when combined with standard dose 5fu/lv and folfiri.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * histological/cytological confirmed diagnosis of gastrointestinal malignancy, except pancreatic cancer * eligible for 5fu/lv or folfiri chemotherapy * ecog 0-1 * able to swallow and tolerate tablets * life expectancy of 3 months exclusion criteria: * unwilling to use acceptable method to avoid pregnancy of partner/self for the entire study period and up to 4 weeks after last dose * women who are pregnant or breastfeeding * pancreatic cancer * known brain metastasis, evidence of leptomeningeal disease * history of thrombo-embolic disease * hemorrhage/bleeding events * uncontrolled or significant cardiovascular disease * any 3 or more of the following risk factors: arterial thrombosis , smoking, hypercholesterolemia, hypertension, obesity (bms\>30) and diabetes * pre-existing thyroid abnormality, not maintained with medication * qtc (fridericia) \>450 msec on two consecutive ecg's * subjects with concomitant second malignancies ( except adequately treated non-melanoma skin, in situ carcinoma of bladder, cervix or breast, early prostate cancer) * any major surgery within 4 weeks of study drug administration * increased levels of both d-dimer and prothrombin fragment 1 +2 * arm b and c only-positive ugt1a1 genotype of ta7/ta7 * history of allergy of brivanib or drug class * history of severe reactions to fluoropyrimidine therapy or irinotecan * prior therapy with brivanib

Keywords: gastro-intestinal cancer, nos
my hearing experience - a study about the effect of personality and lifestyle on everyday hearing

Conditions: Hearing Impairment; Hearing Loss

Summary: the primary purpose of this study is to investigate how personality, motivation \& auditory lifestyle relate to hearing aid satisfaction \& acceptance for first-time hearing aid users. as such, first-time hearing aid users will be followed via an app for a period of six months. they will answer baseline questionnaires about personality, lifestyle and hearing aid expectations before the first fit. after the hearing aid fitting, they will be prompted by the app to answer questionnaires about their hearing aid experience at weeks 2, 4, 8, 12, 16, 20 and 24.


Eligibility criteria:
inclusion criteria: * 18-85 years of age * sensorineural hearing loss within the hearing aid's fitting range * fluency in local language * first-time hearing aid user * experienced smartphone and app user * must sign the informed consent exclusion criteria: * severe cognitive impairment that would preclude the ability to perform the necessary tasks (as judged by the hcp) * inability for the tps to travel to the clinic during the study period * complex hearing disorders such as ménière's
bioware for aud and ptsd

Conditions: PTSD; Alcohol Use Disorder

Summary: this study examines the ability of an innovative telehealth technology system to enhance concurrent treatment of ptsd and substance use disorders using prolonged exposure (cope) talk-therapy for individuals with posttraumatic stress disorder (ptsd) and alcohol use disorder.


Eligibility criteria:
inclusion criteria: 1. male or female; aged 18-70 years. 2. able to provide written informed consent. 3. meet dsm-5 diagnostic criteria for current moderate to severe alcohol use disorder. 4. meet dsm-5 diagnostic criteria for current ptsd. 5. participants taking psychotropic medications will be required to be maintained on a stable dose for at least 4 weeks before study initiation. exclusion criteria: 1. meet dsm-5 criteria for a history of or current psychotic or bipolar disorders. 2. current suicidal or homicidal ideation and intent. 3. psychotropic medications which have been initiated during the past 4 weeks. 4. acute alcohol withdrawal. 5. pregnancy or breastfeeding for people of childbearing potential. 6. currently enrolled in evidence based behavioral treatment for aud or ptsd. 7. implanted electronic devices of any kind, including pacemakers, electronic infusion pumps, stimulators, defibrillators or similar.
a biomarker stress test for detection of early osteoarthritis

Conditions: Osteoarthritis

Summary: veterans have much higher risk of osteoarthritis (oa) then the general population. knee oa is common among veterans and is a leading cause of disability. the earliest stages of oa development, where the joint cartilage wears away, is usually painless. by the time veterans experience symptoms, the oa is typically advanced and there is nothing that can be done except palliation until the joint is replaced with metal and plastic. if there was a blood test to provide early warning of cartilage wear and joint deterioration, veterans could potentially be treated early enough to slow down or even prevent oa. so far, development of such a blood test has proved elusive. the investigators propose a new method to amplify the signs of cartilage wear in the blood by challenging the affected joint with a walking task. similar to a cardiac stress test, this walking challenge may help to separate joints at risk from healthy joints. the investigators will also see if this 'oa stress test' can show if a simple and inexpensive load-modifying shoe can improve joint health in veterans with early knee oa.


Eligibility criteria:
inclusion criteria: * age 18-80 years * symptomatic medial compartment knee oa (kl grades 0-2) * full weight-bearing status * able to walk for 30 minutes or longer * able to undergo mri scan * agreement and ability to use provided shoe as primary walking shoe (4 or more hours a day) during the 6 month study period exclusion criteria: * inflammatory arthritis, gout or recurrent pseudogout * patellofemoral or lateral compartment disease that is equal to or more extensive than medial disease * symptomatic oa of other lower extremity joints * bmi \>35 kg/m2 * prior structural surgery of the knee except for medial meniscectomy performed \> 6 months prior * use of shoe insert or hinged knee brace * pes planus, and/or unusual foot size or shape
comparison of mri and molecular breast imaging in breast diagnostic evaluation

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the sensitivity of molecular breast imaging (mbi) relative to mri of the breast in patients undergoing mri for a clinical concern, or abnormal diagnostic mammogram and/or ultrasound study.

background: breast mri has excellent sensitivity, but is very expensive and suffers from low specificity. additional benign biopsies are prompted by mri in 24-40% of patients. molecular breast imaging (mbi) is a new nuclear medicine technique developed at mayo. preliminary mbi results indicate a sensitivity of \~88% for the detection of tumors \< 10 mm. the cost of an mbi procedure is expected to be a factor of 5 less than an mri examination. hypothesis: mbi has a comparable sensitivity to mri at a significantly lower cost. study design: a total of 120 patients will be studied. all patients will have been scheduled for bilateral breast mri at mayo clinic rochester for a clinical concern, problem solving, or abnormal mammogram and/or ultrasound study. all patients will undergo mbi within 3 weeks of the mri examination. potential outcomes: this study will provide valuable information on the sensitivity of mbi relative to mri, and to determine if this new technique can be eventually developed as an alternative to mri for problem solving.

Eligibility criteria:
inclusion criteria: * this study will include a population of women aged 25 or older who are scheduled for a breast mri examination at mayo clinic rochester. * patients must not be lactating or pregnant. * all women of child-bearing potential must have had a negative urine pregnancy test result within 2 days prior to the mbi study. * women who are scheduled for a breast mri examination for a clinical concern, problem solving or for further evaluation of invasive breast cancer (e.g. pre-operative staging of known breast cancer). exclusion criteria: * they are unable to understand and sign the consent form * they are pregnant or lactating * they are physically unable to sit upright and still for 40 minutes. * the breast mri is for screening purposes or to determine the status of breast augmentation. * they have undergone breast surgery within the previous year

Keywords: benign breast disease breast mri mammography ultrasound molecular breast imaging breast cancer
different cold application times on ecchmosis, edema and pain after rhinoplasty

Conditions: Rhinoplasty; Cryotherapy Effect; Nurse's Role

Summary: the aim of this study is to investigate the effects of different cold application times with cold gel pads after rhinoplasty on eyelid edema, eye ecchymosis and pain. a total of 60 patients undergoing rhinoplasty were divided into two groups by simple randomization method. cold application applied to short term group for 4 hours and to long term group for 48 hours. cold application was applied around both eyes with cold gel pads for 20 minutes per hour. pain was evaluated with the visuel analog scale, ecchymosis with eyelid ecchymosis score, and edema with eye-edema score. edema and ecchymosis were evaluated on the 1st and 4th hours and 2nd day. pain conditions were evaluated before and after analgesics for 1, 4 hours and 2 times daily.

the research was carried out between january 2015 and march 2017 in an education and research hospital with a capacity of 26 beds. the research was suspended between july 2015 and january 2016. patients who underwent rhinoplasty / septorhinoplasty operation between january 2015 and march 2017 with open or closed technique were included in the study. the study included patients who were 18 years of age or older who underwent a rhinoplasty / septorhinoplasty operation voluntarily. patients who had cold allergy, refused to participate, applied outside of the research protocol and required re-operation in the early postoperative period due to complications were excluded from the study. all patients were provided with training and brochures for preoperative, intraoperative and postoperative periods. the cold application was done with gel pads of the same size and weight (13 cm x 13 cm-approximately 100 g) for 20 minutes per hour. cold application was performed by the researcher in both groups for the first 4 hours. the patients in the short-term cold application group were given cold application by the researcher for 4 hours and 20 minutes per hour and the cold application was terminated. in the long-term application group, the first 4 hours of cold application were done by the researcher. cold application after 4 hours; jel pads was applied at home by the patient's relative in accordance with the training given on the cold application protocol.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * who underwent rhinoplasty / septorhinoplasty * voluntarily participated in the study exclusion criteria: * patients with cold allergy, * refused to participate, * performed outside the research protocol, * required early re-operation due to postoperative complications